Group 1 - The chemical pharmaceutical sector experienced a decline of 0.72% on January 28, with Bibete leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the chemical pharmaceutical sector included Guangshengtang, which rose by 14.00% to a closing price of 105.01, and Xinnowei, which increased by 12.90% to 46.21 [1] Group 2 - Bibete saw a significant decline of 13.61%, closing at 46.26, with a trading volume of 103,400 shares and a transaction value of 4.92 million [2] - The sector experienced a net outflow of 1.74 billion in main funds, while retail investors saw a net inflow of 1.274 billion [2] - The top stocks by main fund inflow included Guangshengtang with 1.65 billion and Xinnowei with 79.25 million [3]

Market Overview - The market experienced fluctuations on January 28, with the Shanghai Composite Index rising by 0.27%, the Shenzhen Component Index increasing by 0.09%, and the ChiNext Index declining by 0.57% [2][12]. - A total of 1,739 stocks rose, 84 stocks hit the daily limit up, while 3,640 stocks fell [3][13]. Sector Performance - Resource stocks surged, with gold stocks leading the gains. Sichuan Gold achieved a four-day limit up, while Zhaojin Mining and Hunan Gold saw three consecutive limit ups [4][14]. - Oil and gas stocks collectively rose, with Tongyuan Petroleum and Zhongman Petroleum hitting the limit up, and China National Offshore Oil Corporation (CNOOC) increasing over 6% to reach a new high [5][16]. - The non-ferrous metals sector strengthened, with Silver Industry (Wei Quan) achieving seven consecutive limit ups, and China Aluminum hitting the limit up, marking a 16-year high [6][17]. - The coal sector also saw gains, with Shanxi Coking Coal and Shaanxi Black Cat hitting the limit up [7][18]. Declines - The pharmaceutical and medical stocks faced adjustments, with Bibete and Baipusais falling over 10% [8][19]. Trading Activity - Significant trading activity was noted, with the HuShen 300 ETF from Huatai-PB exceeding 30 billion yuan in trading volume, and other ETFs like the HuShen 300 ETF from E Fund and the CSI 500 ETF also surpassing 20 billion yuan [9][20]. - A report from CITIC Securities indicated that in previous bull markets, overheating trading conditions prompted cooling policies to prevent severe consequences, suggesting that the current proactive cooling measures are aimed at regulating market momentum without altering the overall positive policy stance [9][20].

Core Viewpoint - The pharmaceutical and medical stocks experienced significant fluctuations, with several companies facing notable declines in their stock prices [2] Group 1: Stock Performance - Bibet fell nearly 15% [2] - Companies such as Baipusais, Zhijiang Biology, Wanfubio, Hualan Vaccine, Yongshun Biology, Hongbo Pharmaceutical, and Nearshore Protein saw declines exceeding 5% [2]

Group 1 - The core point of the news is that Bibeite experienced a decline in stock price and trading volume on January 27, with a drop of 2.37% and a total transaction amount of 214 million yuan [1] - On January 27, Bibeite had a financing buy amount of 21.59 million yuan, with a net financing purchase of 4.36 million yuan after repaying 17.22 million yuan [1][2] - As of January 27, the total balance of margin trading for Bibeite was 155 million yuan, which represents 6.23% of its circulating market value [2] Group 2 - Bibeite, established on January 19, 2012, is located in the Guangzhou High-tech Industrial Development Zone and focuses on the independent research and development of innovative drugs [2] - As of January 20, the number of shareholders for Bibeite was 13,000, a decrease of 7.87% from the previous period, while the average circulating shares per person increased by 8.55% to 3,560 shares [2] - For the period from January to September 2025, Bibeite reported zero revenue and a net loss attributable to shareholders of 107 million yuan [2]

Group 1 - The company, Bibet (688759.SH), has announced a projected net loss for the year 2025, estimating a net profit attributable to shareholders of between -166 million yuan and -136 million yuan, with a net profit excluding non-recurring gains and losses expected to be between -188 million yuan and -158 million yuan [1] - From 2022 to 2024, Bibet reported no operating revenue, with net profits attributable to ordinary shareholders of -188.34 million yuan, -172.76 million yuan, and -55.99 million yuan respectively; net profits excluding non-recurring gains and losses were -207.49 million yuan, -187.77 million yuan, and -158.05 million yuan respectively [1] - The net cash flow from operating activities for the same period was -127.67 million yuan, -127.37 million yuan, and -89.61 million yuan respectively [1] Group 2 - Bibet was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2025, issuing 90 million shares at a price of 17.78 yuan per share [2] - The total amount raised from the initial public offering (IPO) was 1.6 billion yuan, with a net amount of 1.49 billion yuan after deducting issuance costs, which was 513.47 million yuan less than originally planned [2] - The company intended to raise 2.004 billion yuan for new drug research and development, the construction of a research and development center in Qingyuan, and to supplement working capital [2]

Group 1 - The core point of the news is that Guanzhou Bibete Pharmaceutical Co., Ltd. has seen a stock price increase of 5.02%, reaching 57.08 CNY per share, with a total market capitalization of 25.688 billion CNY as of January 26 [1] - The company specializes in the independent research and development of innovative drugs and was established on January 19, 2012, with its listing date set for October 28, 2025 [1] Group 2 - According to data, Huaxia Fund has a significant holding in Bibete, with the Huaxia CSI Photovoltaic Industry ETF (012885) holding 2,789 shares, accounting for 0.01% of the fund's net value, making it the sixth largest holding [2] - The Huaxia CSI Photovoltaic Industry ETF has a current scale of 373 million CNY and has achieved a return of 16.54% this year, ranking 446 out of 5,579 in its category [2] - The fund has a one-year return of 56.88%, ranking 1,128 out of 4,270, but has experienced a loss of 28.7% since its inception on August 17, 2021 [2] Group 3 - The fund manager of the Huaxia CSI Photovoltaic Industry ETF is Li Jun, who has been in the position for 8 years and 49 days, managing a total asset size of 95.667 billion CNY [3] - During his tenure, the best fund return achieved was 146.12%, while the worst return was -39.56% [3]

北京商报讯（记者 丁宁）1月23日晚间，必贝特（688759）发布2025年年度业绩预亏公告显示，经财务 部门初步测算，预计2025年年度实现归属净利润与上年同期（法定披露数据）相比，将出现亏损，实现 归属净利润为-1.36亿元至-1.66亿元。 必贝特表示，报告期内，公司尚未实现营业收入，与经营相关的研发投入和运营支出等持续发生。公司 共有1款产品获批上市，1款产品处于III期临床试验阶段，1款产品已获准开展III期临床试验，5款产品处 于I期临床试验阶段，另有多款产品处于临床前研究阶段。因公司尚未实现营业收入并保持较高的研发 投入，预计2025年度将出现亏损。 ...

证券日报网讯1月23日，必贝特在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东人数 为13048户。 ...

Group 1 - The chemical pharmaceutical sector increased by 0.91% on January 23, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] - Guangshantang's stock price rose by 20.00% to 96.28, with a trading volume of 185,500 shares [1] Group 2 - The main funds in the chemical pharmaceutical sector experienced a net outflow of 487 million yuan, while retail investors saw a net inflow of 1.12 billion yuan [2] - The stock performance of several companies showed varied results, with some experiencing declines, such as Xingqi Eye Medicine down 4.86% [2] - The trading volume and turnover for various companies in the sector were significant, with notable figures such as 1.62 billion yuan for Xingqi Eye Medicine [2] Group 3 - Guangshantang had a net inflow of 396 million yuan from main funds, while retail investors had a net outflow of 136 million yuan [3] - Other companies like Hancheng Group and Shutaishen also showed significant net inflows and outflows, indicating varied investor sentiment [3] - The data reflects a mixed investment environment within the chemical pharmaceutical sector, with both institutional and retail investors actively participating [3]

证券代码：688759 证券简称：必贝特 公告编号：2026-002 广州必贝特医药股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年年度实现归属于母公司所有者的净 利润与上年同期（法定披露数据）相比，将出现亏损，实现归属于母公司所有者 的净利润为-16,600 万元到-13,600 万元。 （2）归属于母公司所有者扣除非经常性损益后的净利润-18,800 万元到 -15,800 万元。 （三）本次业绩预告情况未经注册会计师审计。 二、上年同期经营业绩和财务状况 （一）利润总额：-5,590.78 万元。归属于母公司所有者的净利润：-5,599.83 万元。归属于母公司所有者的扣除非经常性损益的净利润：-15,804.87 万元。 （二）每股收益：-0.16 元/股。 三、本期业绩预亏的主要原因 报告期内，公司尚未实现营业收入，与经营相关的研发投入和运营支出等持 续发生。公司共有 1 款产品获批上 ...